Market Eyes LiveCharles River Laboratories International, Inc. (CRL) Stock Rating & Analysis
MELANY's data-driven read on Charles River Laboratories International, Inc. · Services-Commercial Physical & Biological Research.
Charles River Laboratories, founded in 1947, is a leading provider of drug discovery and development services. Its research model and services segment is the leading provider of animal models for laboratory testing, breeding and delivering research models with specific genetic characteristics for preclinical studies worldwide. Its discovery and safety assessment segment covers the services needed to move a drug through early development, including discovery services.
Why CRL scores 56/100
MELANY scores Charles River Laboratories International, Inc. 56/100 by weighing eight factors. Here is how CRL breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- PEG ratio 0.12 (< 1 = undervalued)
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- Price +24.8% above 50-day MA
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for CRL
- Trading near 52-week high, limited upside without new positive catalyst
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Charles River Laboratories International, Inc. sits in the Healthcare sector theme, which MELANY currently rates 56/100 for strength. Theme strength feeds CRL's momentum and catalyst factors above.
CRL trade plan (members only)
MELANY has a full position plan for Charles River Laboratories International, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates CRL
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Charles River Laboratories International, Inc.'s 56/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about CRL
Is Charles River Laboratories International, Inc. (CRL) a buy?
As of 2026-08-25, MELANY rated Charles River Laboratories International, Inc. Promising with a composite score of 56/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Charles River Laboratories International, Inc.'s MELANY score?
Charles River Laboratories International, Inc. (CRL) has a MELANY composite score of 56/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the CRL stock rating calculated?
MELANY scores CRL from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Charles River Laboratories International, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Charles River Laboratories International, Inc. (CRL) Promising with a composite of 56/100 as of 2026-08-25. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the CRL stock price forecast?
MELANY does not publish price targets or forecasts for CRL. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 56/100 across eight factors for Charles River Laboratories International, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is CRL stock overvalued or undervalued?
MELANY's valuation factor currently reads 61/100 for Charles River Laboratories International, Inc., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives CRL's read.
What price should I buy CRL at?
Rather than chasing the current price, MELANY computes a smart entry zone for CRL: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying CRL stock?
The top risks MELANY currently flags for Charles River Laboratories International, Inc.: Trading near 52-week high, limited upside without new positive catalyst; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Charles River Laboratories International, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 40/100 for Charles River Laboratories International, Inc., and earnings track record, at 79/100. The 56/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will CRL stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 84/100 for CRL right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this CRL rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-25. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores CRL continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
CRL's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.